🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. MRTX1719

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  2. MYCOPHENOLATE MOFETIL, Rilvegostomig, RAMUCIRUMAB, INFLIXIMAB

    AstraZeneca AB

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  3. MaaT033 capsule

    Regeneron UK Limited

    NSCLC (Advanced Non-small Cell Lung Cancer)

    phase 2 small molecule active

    1 trial

  4. Mekinist 2 mg film-coated tablets, Hydroxychloroquine sulfate Accord 200mg film-coated tablets, Mekinist 0.5 mg film-coated tablets

    Ningbo Cancer Hospital

    Metastatic refractory Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  5. Mektovi 15 mg film-coated tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Braftovi 75 mg hard capsules

    Ningbo Cancer Hospital

    BRAF(V600) mutation-positive melanoma with brain metastasis (MBM)

    phase 2 small molecule active

    1 trial

  6. Mektovi 15 mg film-coated tablets, Tyverb 250 mg film-coated tablets, Vinorelbine Accord 10 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    metastatic colorectal cancer with a proven RAS mutation after failure of standard systemic treatment regimens including at least 5- FU/capecitabine-oxaliplatin and irinotecan based standard treatment (unless contra-indications for either oxaliplatin or irinotecan)

    phase 2 small molecule active

    1 trial

  7. Midazolam-ratiopharm® 2 mg/ml orale Lösung, JNJ-42756493, JNJ-42756493, Metformin HEXAL 1000 mg Filmtabletten, JNJ-42756493

    Janssen-Cilag International N.V.

    Urothelial cancer

    phase 2 small molecule active

    1 trial

  8. Mifepristone

    CORCEPT THERAPEUTICS INC

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule terminated

    1 trial

  9. Mitomycin C

    HALOZYME THERAPEUTICS, INC.

    Bladder Cancer

    phase 2 small molecule completed

    1 trial

  10. Mitomycin C

    United Therapeutics Europe Ltd

    Bladder Cancer

    phase 2 small molecule active

    1 trial

  11. MoLuoDan

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Precancerous Condition

    phase 2 small molecule active

    1 trial

  12. Motixafortide

    Regeneron UK Limited

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  13. Myocet (Non-pegylated liposomal doxorubicin (NPLD))

    Sana Biotechnology

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  14. NAP (Naptumomab estafenatox)

    BRIGHT MINDS BIOSCIENCES INC.

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  15. NDV01 intravesical controlled release formulation of gemcitabine and docetaxel

    RELMADA THERAPEUTICS, INC.

    Non Muscle Invasive Bladder Cancer

    phase 2 small molecule active

    1 trial

  16. NEO-201 in combination with pembrolizumab

    Chongqing Precision Biotech Co., Ltd

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  17. NERATINIB

    PUMA BIOTECHNOLOGY, INC.

    Stage IV (Metastatic) Breast Cancer

    phase 2 small molecule terminated

    1 trial

  18. NERATINIB, Sindiar 2 mg cápsulas duras

    Ningbo Cancer Hospital

    HER2 positive (HER2+), Hormone Receptor positive (HR+) Early-stage Breast Cancer.

    phase 2 small molecule active

    1 trial

  19. NIVOLUMAB, TEDOPI

    Fondazione Telethon ETS

    metastatic non-small-cell lung cancer

    phase 2 small molecule active

    1 trial

  20. NK cell and PD-1 antibody

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 other completed

    1 trial

  21. NKTR-102

    Nektar Therapeutics UK Limited

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  22. NKTR-214

    Nektar Therapeutics UK Limited

    Head and Neck Cancer

    phase 2 small molecule terminated

    1 trial

  23. NKTR-214

    Nektar Therapeutics UK Limited

    Non-Small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  24. NKTR-255

    Nektar Therapeutics UK Limited

    Lung Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources